Cornelissen Lenneke A M, Van Vliet Sandra J
Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, 1081 HZ, The Netherlands.
Biomolecules. 2016 May 3;6(2):26. doi: 10.3390/biom6020026.
The appearance of aberrant glycans on the tumor cell surface is one of the emerging hallmarks of cancer. Glycosylation is an important post-translation modification of proteins and lipids and is strongly affected by oncogenesis. Tumor-associated glycans have been extensively characterized regarding their composition and tumor-type specific expression patterns. Nevertheless whether and how tumor-associated glycans contribute to the observed immunomodulatory actions by tumors has not been extensively studied. Here, we provide a detailed overview of the current knowledge on how tumor-associated O-glycans affect the anti-tumor immune response, thereby focusing on truncated O-glycans present on epithelial tumors and mucins. These tumor-associated O-glycans and mucins bind a variety of lectin receptors on immune cells to facilitate the subsequently induction of tolerogenic immune responses. We, therefore, postulate that tumor-associated glycans not only support tumor growth, but also actively contribute to immune evasion.
肿瘤细胞表面异常聚糖的出现是癌症新出现的特征之一。糖基化是蛋白质和脂质重要的翻译后修饰，且受到肿瘤发生的强烈影响。肿瘤相关聚糖在其组成和肿瘤类型特异性表达模式方面已得到广泛表征。然而，肿瘤相关聚糖是否以及如何促成肿瘤所观察到的免疫调节作用尚未得到广泛研究。在此，我们详细概述了目前关于肿瘤相关O-聚糖如何影响抗肿瘤免疫反应的知识，从而聚焦于上皮肿瘤和粘蛋白上存在的截短O-聚糖。这些肿瘤相关O-聚糖和粘蛋白与免疫细胞上的多种凝集素受体结合，以促进随后耐受性免疫反应的诱导。因此，我们推测肿瘤相关聚糖不仅支持肿瘤生长，还积极促成免疫逃逸。
